Home>Topics>Stocks>Acorda Therapeutics

Acorda Therapeutics ACOR

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Ampyra faces generic threat

      Headlines

      Thu, 26 Jun 2014

      Actavis ( ACT ) files an ANDA for a generic version of Acorda Therapeutics ' ( ACOR ) MS drug Ampyra ( dalfampridine ) Extended Release Tablets, 10 mg. The company intends to vigorously defend its IP rights and

    2. Acorda's multiple sclerosis drug faces generic threat

      Headlines

      Thu, 26 Jun 2014

      June 26 (Reuters) - Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda 's multiple sclerosis treatment, Ampyra.

    3. Acorda prices debt

      Headlines

      Wed, 18 Jun 2014

      Acorda Therapeutics ( ACOR ) prices its $300M aggregate principal amount of convertible senior notes due 2012. The notes will bear an interest rate of 1

    4. Midday Gainers / Losers

      Headlines

      Tue, 17 Jun 2014

      17% . MCRS +17% . INSY +15% . SCTY +16% . FST +16% . GWPH +15% . Top 10 Losers: PRPH -10% . REI -10% . BODY -7% . LITB -7% . ORMP -7% . DOM -7% . EDN -7% . QKLS -6% . ACOR -6% . CSLT -6% . Post your comment!

    5. Acorda to offer debt

      Headlines

      Mon, 16 Jun 2014

      Acorda Therapeutics ( ACOR +0.5% ) plans to offer $300M aggregate principal amount of convertible senior notes due 2021 pursuant to a shelf registration

    6. We're Boosting Biogen Idec's Fair Value Estimate Following European Approval of Fampyra

      Commentary

      Wed, 27 Jul 2011

      this week. Fampyra, which is marketed in the United States under the trade name Ampyra by the firm's partner Acorda Therapeutics ACOR , is the first approved treatment to improve walking in patients with multiple sclerosis. Fampyra now marks

    7. Elan's 2010 Results In Line; Enthusiasm for Growth Potential Tempered by High-Risk Pipeline

      Commentary

      Tue, 8 Feb 2011

      EDT) were flat, as patent expirations on older products countered strong manufacturing and royalty revenue from Ampyra, Acorda and Biogen-Idec's BIIB new oral MS drug. Tysabri's net new-patient adds actually fell in the fourth quarter, as compared

    8. Tysabri Carries Elan in 2Q

      Commentary

      Thu, 22 Jul 2010

      exploring the possible sale of this business. Royalties on Acorda 's ACOR recently approved multiple sclerosis drug Ampyra will be key to EDT's future growth, and Acorda 's second-quarter results in August will give us a

    « Prev12Next »
    Content Partners